Maymetsi

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a Biguanide / DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels when used in combination with diet and exercise.

GNH USA supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets and providing reliable distribution.

Maymetsi combines metformin and sitagliptin to treat disorders of glucose metabolism, primarily type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels to improve overall glycaemic control. - Adjunct to lifestyle modification: enhances the effect of diet and exercise on blood sugar regulation. - Inadequate control on metformin alone: provides additional DPP‑4 inhibition for patients needing further glucose reduction.

Adverse reactions may occur with any antidiabetic therapy and should be monitored.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Hypoglycaemia: especially when combined with other glucose‑lowering agents. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic failure: signs of liver dysfunction. - Renal impairment worsening: especially in patients with pre‑existing kidney disease.

Before prescribing Maymetsi, clinicians should consider several safety factors.

- Renal function: assess baseline creatinine clearance and monitor regularly. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in patients with significant hypoxia, severe renal dysfunction, or alcohol abuse. - Pregnancy and lactation: safety not established; consider alternative therapy. - Drug interactions: review concomitant medicines for additive hypoglycaemia risk. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Maymetsi may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Phenformin or other contraindicated biguanides: increased risk of lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels. - Iodinated IV contrast agents: can impair renal function, necessitating temporary metformin discontinuation.

Moderate Interactions (Monitor Closely): - Sulfonylureas: heightened risk of hypoglycaemia. - Diuretics (especially thiazides): may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes during combined use.